

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089023 A1

(51) International Patent Classification⁷: A61L 27/30,
A61F 2/30

MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/GB03/01264

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 25 March 2003 (25.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0208642.9 16 April 2002 (16.04.2002) GB

(71) Applicant (for all designated States except US): ACCENTUS PLC [GB/GB]; 329 Harwell, Didcot, Oxfordshire OX11 0QJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PICKFORD, Martin, Edward, Lee [GB/GB]; 37 Downland Close, Locks Heath, Southampton, Hampshire SO31 6WB (GB). TURNER, Andrew, Derek [GB/GB]; 17 Loyd Close, Abingdon, Oxfordshire OX14 1SR (GB).

(74) Agents: MANSFIELD, Peter, Turquand et al.; Accentus plc, Patents Dept, 329 Harwell, Didcot, Oxfordshire OX11 0QJ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/089023 A1

(54) Title: METAL IMPLANTS

(57) Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer may be grown from the metal substrate, by anodising, and the biocidal material incorporated in it by ion exchange. Alternatively the layer may be deposited by electroplating, followed by diffusion bonding so as to become integral with the metal substrate. In either case, silver is a suitable biocidal material; and both the release rate and the quantity of biocidal material should be low to avoid toxic effects on body cells. Electropolishing the surface before formation of the surface layer is also beneficial, and this may be achieved by electropolishing.

Metal Implants

This invention relates to metal implants for use in surgical procedures, and in particular to the 5 introduction of a biocidal material into such implants to suppress or control infection.

Various surgical procedures require the use of implants. For example cancerous bone may be removed, in 10 prosthetic surgery, to be replaced by a metal implant. Such an implant may for example be of titanium alloy, which is very strong and relatively light. To ensure a hard-wearing surface the provision of a titanium nitride coating has been suggested. There is furthermore a risk 15 of introducing infection when implanting such metal implants, and it has been suggested that metallic silver might be electroplated onto metal implants, the silver being a biocidal material that can control infection without causing toxic effects to the patient. However 20 such coatings, whether of titanium nitride or silver, may be undercut due to corrosion from body fluids, so that the coating may detach from the implant, which may can increase wear and cause tissue damage.

25 According to the present invention there is provided an implant for use in a surgical procedure, the implant comprising a metal substrate and a surface layer that is integral with the metal substrate, the layer incorporating a biocidal metal deposited from a solution.

30

The invention also provides a method of producing such an implant.

Such an integral surface layer may be generated by 35 growing the layer from the metal itself, for example by an anodising process; or alternatively by depositing the

- 2 -

layer for example by electroplating, followed by diffusion bonding so that the layer becomes integral with the metal of the implant. Anodising forms an adherent oxide layer, although if it is carried out in phosphoric 5 acid then a phosphate may be formed. Such an adherent phosphate layer may also be modified to form a hydroxyapatite layer, which can stimulate bone growth.

The biocidal material should preferably be effective 10 for at least 6 weeks, preferably for up to 6 months after surgery, and the release rate should be low to avoid toxic effects on body cells. Furthermore the total quantity of biocidal material is preferably also limited to minimize any toxic effects.

15

It is also desirable if the surface is highly polished before production of the surface layer. This may for example be achieved by electropolishing.

20 In principle, a range of different metals may be used for the biocidal metal. In particular, if the layer is a metal layer deposited by electroplating then it clearly must be stable to corrosion. Gold, platinum, iridium and palladium would be potentially suitable, 25 although expensive; silver is preferable as it is not particularly soluble in body fluids due to the presence of chloride ions and the low solubility of silver chloride. If the surface layer contains the biocidal metal in ionic form, then a wider range of metals would 30 be possible. In addition to the elements already mentioned, copper, tin, antimony, lead, bismuth and zinc might be used as ions combined into an insoluble matrix for example of metal oxide or metal phosphate. The rate 35 of release would be controlled, in this case, primarily by the strength of the absorption of the metal ions in the matrix.

- 3 -

The metals that may be used to make such prosthetic implants are typically a form of stainless steel, a titanium alloy, or a cobalt/chromium alloy, although zirconium could also be used. The standard alloys for 5 this purpose are titanium 90% with 6% aluminium and 4% vanadium (British standard 7252), or chromium 26.5-30%, molybdenum 4.5-7%, and the remainder cobalt (British standard 7252 part 4).

10 Preferably the implant is initially polished to provide a very smooth surface. Both stainless steel (chromium/iron/nickel) and cobalt/chromium alloy can be electro-polished using as electrolyte a mixture of phosphoric acid and glycerine, or a mixture of phosphoric 15 acid and sulphuric acid. Titanium alloy can be electro-polished using acetic acid, or a mixture of nitric and hydrofluoric acids. Alternatively the implants might be subjected to a combination of anodic passivation with mechanical polishing, which may be referred to as 20 electrolining, this process removing the oxide that protects surface roughness, the surface at that point then being electrochemically re-passivated, so producing a mirror-smooth finish. Various electrolytes are suitable for this purpose, including nitric acid mixed 25 with sulphuric acid, sodium hydroxide, sodium phosphate, or sodium hydroxide mixed with sodium nitrate.

After polishing the surface of the metal, either silver deposition or surface conversion can take place. 30 Considering surface conversion first, a layer of metal oxide or phosphate may be formed by anodising in a suitable electrolyte, so that the oxide or phosphate layer builds out from the surface of the metal. Biocidal metal ions can then be absorbed from an aqueous salt 35 solution into the oxide or phosphate matrix, for example the ions Ag^+ or Cu^{++} . Cations of palladium, platinum or

- 4 -

even ruthenium could be absorbed in a similar way. If desired, deposited silver, platinum or palladium ions could then be converted to metal, or deposited ruthenium ions converted to insoluble RuO_2 , within the oxide or 5 phosphate surface coating, this reaction being performed chemically or electrochemically or by light.

Considering now silver deposition, the coating should be thin to prevent toxic effects. A high degree 10 of adherence to the underlying metal can be ensured by first removing the surface oxide layer by anodic etching, followed by a brief reversal of polarity in the presence of appropriate ions, so as to cover the surface with a thin coating of silver. This may be repeated to ensure 15 there are no pin-holes. The plating electrolyte may include hydrofluoric acid, or may be an alkaline cyanide electroplating electrolyte. After deposition, the silver coating should be diffusion bonded so as to form an inter-metallic layer, by heating the implant to an 20 elevated temperature. Typically it should be heated to above 800°C , preferably between 810°C and 950°C , in an inert atmosphere for example of argon for a period of between 1 and 6 hours. This substantially eliminates the risk of coating delamination. However with titanium- 25 based implants the temperature must not exceed 850°C as titanium would undergo a phase change from alpha to beta form above this temperature.

In place of silver, other metals such as platinum or 30 palladium may be electro-deposited and then thermally treated in a similar fashion so as to form an inter-metallic layer.

The invention will now be further and more 35 particularly described, by way of example only.

- 5 -

A hip implant is made of titanium alloy (Ti/Al/V). The implant is cleaned ultrasonically using first acetone as the liquid phase, and then a 1 M aqueous solution of sodium hydroxide, and is then rinsed in de-ionised water.

5 The cleaned implant is then immersed in a stirred 12 weight % solution of phosphoric acid, and is anodised for 2 hours at a maximum voltage of 10 V and a maximum current of 10 mA/cm², so as to form a surface coating of titanium phosphate. It is then rinsed in de-ionised

10 water again. The surface, which is initially pale grey, turns to a darker matt grey as a consequence of the anodising, with a slightly yellow hue.

The implant is then immersed in a stirred 0.1 M aqueous solution of silver nitrate, and left for 2 hours.

15 As a result of ion exchange there is consequently some silver phosphate in the titanium phosphate coating. The implant is then ready to be implanted. During exposure to body fluids there will be a slow leaching of silver

20 ions from the phosphate layer, so that any bacteria in the immediate vicinity of the implant are killed. Infection arising from the implant is therefore suppressed.

25 Experimental samples of this titanium alloy were cleaned, anodised to form a layer of titanium phosphate, and then subjected to ion exchange to form silver phosphate, following the procedure described above. One sample was placed in direct daylight for 110 hours; the

30 exposed surface became darkened as a result of this exposure to daylight, indicating the formation of silver metal by photo-reduction. The other sample was immersed in a solvent containing a mixture of 4 M nitric acid and 0.5 M sodium fluoride (equivalent to hydrofluoric acid)

35 to dissolve the coating. The dark grey surface coating was removed completely within 3 minutes, leaving a

- 6 -

silver-grey finish. The resulting solution was analyzed for the presence of silver by atomic absorption spectrometry, and the concentration of silver was found to be equivalent to an average surface loading of 73.5 $\mu\text{g/cm}^2$.

- 7 -

Claims

1. An implant for use in a surgical procedure, the implant comprising a metal substrate and a surface layer that is integral with the metal substrate, the layer incorporating a biocidal metal deposited from a solution.
2. An implant as claimed in claim 1 wherein the integral surface layer is generated by growing the layer from the metal.
3. An implant as claimed in claim 2 wherein the surface layer is generated by an anodising process.
- 15 4. An implant as claimed in claim 3 wherein the surface layer comprises a metal phosphate.
5. An implant as claimed in any one of claims 2 to 4 wherein the biocidal metal comprises metal ions absorbed 20 within the surface layer.
6. An implant as claimed in claim 5 wherein the biocidal material comprises silver.
- 25 7. An implant as claimed in claim 1 wherein the integral surface layer is generated by first depositing the layer and then subjecting the layer and the substrate to diffusion bonding so that the layer becomes integral with the metal of the substrate.
- 30 8. An implant as claimed in any one of the preceding claims wherein the surface of the implant is highly polished before provision of the surface layer.

35

- 8 -

9. A method of making an implant for use in a surgical procedure, the implant comprising a metal substrate, and the method comprising forming a surface layer on the substrate which is integral with the metal substrate, and 5 incorporating a biocidal metal in the layer by deposition from a solution.

10. A method as claimed in claim 9 comprising anodising the surface of the substrate to form the integral surface 10 layer.

11. A method as claimed in claim 10 wherein silver ions are incorporated in the surface layer by contact with a solution containing silver ions.

15

12. A method as claimed in claim 9 wherein the surface layer is a metal layer deposited by electroplating, and is subsequently rendered integral with the substrate by a heat treatment to cause diffusion bonding.

20

INTERNATIONAL SEARCH REPORT

PCT/GB 03/01264

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61L27/30 A61F2/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 113 636 A (OGLE MATTHEW F) 5 September 2000 (2000-09-05) column 4, line 15 - line 21 column 6, line 43 - line 62 column 7, line 1 - line 29 column 8, line 18 - line 35 column 8, line 57 - line 67 ---	1,2,4-6, 9,11
X	WO 99 01089 A (UNIV BROWN RES FOUND ;VALENTINI ROBERT F (US)) 14 January 1999 (1999-01-14) page 6, line 2 - line 5 page 8, line 6 -page 10, line 22 page 17, line 6 - line 29 page 19, line 1 - line 13 ---	1,2,4,5, 7,9,12

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

6 June 2003

Date of mailing of the international search report

23/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Storer, J

BEST AVAILABLE COPY


INTERNATIONAL SEARCH REPORT

PCT/GB 03/01264

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 336 617 A (SHIKITA TAKUJI ET AL) 29 June 1982 (1982-06-29) column 2, line 28 - line 66 ----	3,10
A	US 5 482 731 A (SALINAS-RODRIGUEZ ARMANDO ET AL) 9 January 1996 (1996-01-09) column 2, line 45 -column 3, line 5 -----	7,12

BEST AVAILABLE COPY



INTERNATIONAL SEARCH REPORT

PCT/GB 03/01264

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 6113636	A	05-09-2000	AU EP JP WO US US	1531599 A 1032431 A2 2001523527 T 9926666 A2 6267782 B1 6190407 B1		15-06-1999 06-09-2000 27-11-2001 03-06-1999 31-07-2001 20-02-2001
WO 9901089	A	14-01-1999	CA EP WO	2301064 A1 1006945 A1 9901089 A1		14-01-1999 14-06-2000 14-01-1999
US 4336617	A	29-06-1982	JP JP JP DE	1446718 C 56102239 A 62054021 B 3101679 A1		30-06-1988 15-08-1981 12-11-1987 17-12-1981
US 5482731	A	09-01-1996	NONE			